三托利德通过NRF2/xCT/GPX4促进宫癌细胞中的铁亡
Miaomiao Feng1,2, Haiwang Wu1, Ling Zhu1
1Department of Gynaecology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Phytotherapy research : PTR
|December 19, 2024
概括
特里普托利德通过铁化诱导癌细胞死亡,这是一种涉及脂质过氧化的过程. 该化合物抑制NRF2/GPX4/xCT通路,为宫癌 (CC) 提供了潜在的新疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 子宫癌 (CC) 对妇女健康构成重大威胁.
- 开发更少的毒性和更有效的CC疗法至关重要.
- 来自Tripterygium Wilford的Triptolide (Tri) 显示出抗瘤的特性.
研究的目的:
- 为了调查Triptolide (Tri) 是否会在宫癌 (CC) 细胞中诱导铁亡.
- 阐明CC中Tri诱导铁灭的潜在分子机制.
- 在CC模型中评估Tri的治疗潜力.
主要方法:
- 在体外:用Tri处理的CC细胞;评估脂质过氧化 (流细胞计,免疫光).
- 通过Western blot探索了分子机制;核实了NRF2/GPX4/xCT轴调节.
- 在体内:使用携带瘤的小鼠模型来评估Tri对瘤生长的影响.
主要成果:
- 在体外,Tri抑制了CC细胞的生长和迁移.
- 通过增加脂质过氧化,Tri显著增强了铁.
- 特里降低了NRF2的表达,从而抑制了GPX4和xCT.
- 过度表达NRF2逆转了Tri对铁亡的作用.
- 通过准NRF2/GPX4/xCT轴,tri显著抑制了体内瘤的生长.
结论:
- 三胺 (Tri) 通过诱导铁亡,对宫癌 (CC) 产生抗瘤作用.
- 该机制涉及NRF2/GPX4/xCT信号通路的抑制.
- 三代表了宫癌治疗的有前途的治疗药物.
更多相关视频
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
12.2K
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.2K
相关概念视频
Necrosis
4.3K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.3K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Electron Transport Chain: Complex I and II
11.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
11.3K
